Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 4
1(25.0%)
N/A
1(25.0%)
4Total
Phase 3(2)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06895746Active Not Recruiting

Multi-omics Study in Citrin Deficiency

Role: collaborator

NCT03651011Not ApplicableCompleted

Navigated Laser In Branch Retinal Vein Occlusion Study

Role: collaborator

NCT02157350Phase 3Completed

The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT

Role: collaborator

NCT02462304Phase 4Unknown

To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema

Role: collaborator

NCT01481870Phase 3Unknown

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma

Role: lead

All 5 trials loaded